Aurigene Oncology
Dr. Reddy's oncology discovery company, with more than 20 programmes in clinical development worldwide through partners and its own small-molecule and cell therapy pipeline.
Overview
Aurigene was established in 2001 as a discovery subsidiary of Dr. Reddy's Laboratories and now describes itself as a clinical-stage biopharmaceutical company focused on cancer therapeutics, with more than 80 integrated discovery projects delivered, 22 programmes in global clinical development and a team of over 350 scientists in Bengaluru and Hyderabad. Its model has been to discover molecules against validated cancer targets and partner them with global companies for clinical development, while building an Indian pipeline that includes a BCMA-directed CAR-T for multiple myeloma developed for the Indian market.
Pages like this
not linked directly; found by shared links- CompanyArcellx
Shares BCMA, Multiple myeloma, CAR-T cell therapy.
- PersonNoopur Raje
Shares BCMA, Multiple myeloma, CAR-T cell therapy.
- TrialLUMMICAR STUDY 1
Shares BCMA, Multiple myeloma, CAR-T cell therapy.
- ProductAnitocabtagene autoleucel
Shares BCMA, Multiple myeloma, CAR-T cell therapy.
- CompanyPoseida Therapeutics
Shares BCMA, Multiple myeloma, CAR-T cell therapy.
- PersonJesús G. Berdeja
Shares BCMA, Multiple myeloma, CAR-T cell therapy.
- PersonNikhil C. Munshi
Shares BCMA, Multiple myeloma, CAR-T cell therapy.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares BCMA, CAR-T cell therapy.